{"id":39285,"date":"2026-01-21T10:05:26","date_gmt":"2026-01-21T09:05:26","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=39285"},"modified":"2026-01-26T15:08:33","modified_gmt":"2026-01-26T14:08:33","slug":"verbesserte-prognose-von-personen-mit-hohem-kardiovaskulaerem-risiko-durch-pcsk-9-hemmung-die-vesalius-cv-studie-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2026\/verbesserte-prognose-von-personen-mit-hohem-kardiovaskulaerem-risiko-durch-pcsk-9-hemmung-die-vesalius-cv-studie-cme","title":{"rendered":"Verbesserte Prognose von Personen mit hohem kardiovaskul\u00e4rem Risiko durch PCSK-9-Hemmung \u2013 Die VESALIUS-CV-Studie [CME]"},"content":{"rendered":"<p>Die Senkung der atherogenen Lipoproteine (Non-HDL-, LDL-Cholesterin, Apolipoprotein\u00a0B) durch Statine hat sich in allen Risikobereichen als wirksam erwiesen, bedeutsame kardiovaskul\u00e4re Ereignisse (MACE = \u201eMajor Adverse Cardiovascular Events\u201c) zu verhindern. Der Nutzen ist qualitativ und quantitativ umso gr\u00f6\u00dfer und tritt umso fr\u00fcher ein, je h\u00f6her das Grundrisiko ist . Ob und inwieweit diese Einsch\u00e4tzung auch f\u00fcr [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die Senkung der atherogenen Lipoproteine (Non-HDL-, LDL-Cholesterin, Apolipoprotein\u00a0B) durch Statine hat sich in allen Risikobereichen als wirksam erwiesen, bedeutsame kardiovaskul\u00e4re Ereignisse (MACE = \u201eMajor Adverse Cardiovascular Events\u201c) zu verhindern. Der Nutzen ist qualitativ und quantitativ umso gr\u00f6\u00dfer und tritt umso fr\u00fcher ein, je h\u00f6her das Grundrisiko ist . Ob und inwieweit diese Einsch\u00e4tzung auch f\u00fcr [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[684,495,1272,3065,71,453,498,456,65,1525,1526,1522,6319],"class_list":["post-39285","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-arteriosklerose","tag-evolocumab","tag-herzinfarkt","tag-hypercholesterinaemie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-myokardinfarkt","tag-pcsk9","tag-pcsk9-antikoerper","tag-pcsk9-hemmer","tag-vesalius-cv-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/39285","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=39285"}],"version-history":[{"count":2,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/39285\/revisions"}],"predecessor-version":[{"id":39343,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/39285\/revisions\/39343"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=39285"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=39285"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=39285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}